Kato, Hidenori
de Souza, Paul
Kim, Sang-We
Lickliter, Jason D.
Naito, Yoichi
Park, Keunchil
Kumar, Sanjeev
Mugundu, Ganesh M.
Bang, Yung-Jue http://orcid.org/0000-0001-6000-4597
Article History
First Online: 7 February 2020
Compliance with Ethical Standards
: The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics [CitationRef removed]. The institutional review boards or independent ethics committees of all investigational sites approved the protocol, and all patients provided written, informed consent.
: This work was supported by AstraZeneca.
: P de Souza is a consultant for Noxopharm Australia Pty Ltd and BioSceptre Australia Pty Ltd. S-W Kim reports an advisory role for AstraZeneca, Lilly, Ono, and Boehringer Ingelheim and research funding from AstraZeneca, Lilly, and Boehringer Ingelheim. Y Naito reports a speakers’ bureau role for AstraZeneca, Bayer, Chugai, Eisai, Eli Lilly, Fuji Film Toyama Chemical, Meiji Seika, Merck Serono, Nippon Kayaku, Novartis, Pfizer, Roche Diagnostics, and Taiho, and research funding from Roche Diagnostics. K Park reports an advisory role for AbbVie, Amgen, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, BluePrint, BMS, Clovis Oncology, Daiichi-Sankyo, Eli Lilly, GSK, Hanmi, Incyte, Kyowa Hakko Kirin, LOXO, Merck KGaA, MSD, Novartis, Ono Pharmaceutical, and Roche and research funding from AstraZeneca and MSD. S Kumar and GM Mugundu are AstraZeneca employees and stock holders. Y-J Bang is a consultant and reports an advisory role for AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, BMS, Eli Lilly, Taiho, Daiich-Sankyo, Astellas, BeiGene, GreenCross, Samyang Biopharm, Hanmi, and Genexine and institutional grants (for clinical trials) from AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, BMS, GSK, Pfizer, Eli Lilly, Boehringer-Ingelheim, MacroGenics, Boston Biomedical, FivePrime, Curis, Taiho, Takeda, Ono, Daiichi-Sankyo, Astellas, BeiGene, GreenCross, CKD Pharma, and Genexine. No potential conflicts of interest were disclosed by the other authors.